PMID: 2095000Jan 1, 1990Paper

The content of fibronectin, fibrinogen, its degradation products and myoglobin in patients with ischemic heart disease

Terapevticheskiĭ arkhiv
L T MalaiaL N Shuliak

Abstract

ELISA using the test systems and a complex of equipment manufactured by Flow Company was employed to study over time the content of fibronectin, fibrinogen, products of its degradation and myoglobin in 178 patients suffering from coronary heart disease (stable and progressive angina pectoris, acute myocardial infarction). The concentration of myoglobin, fibronectin, fibrinogen and products of its degradation was established to depend on the gravity of coronary heart disease and the tame elapsed since the disease onset. In patients with progressive disease, there was an increased consumption of fibronectin which may be due both to its expenditure during blood coagulation and fulfillment of angioprotective function because of exacerbation of systemic atherosclerosis.

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Terapevticheskiĭ arkhiv
R T AlekperovL P Anan'eva
Acta Medica Croatica : C̆asopis Hravatske Akademije Medicinskih Znanosti
K Catipović-VeselicaB Catipović
Patologicheskaia fiziologiia i èksperimental'naia terapiia
V V NikolaevskiĭI F Shinkarchuk
Indian Journal of Experimental Biology
A H SubrattyV Jowaheer
© 2021 Meta ULC. All rights reserved